Table 1.
Baseline demographics and characteristics in AQP4–IgG–seropositive participants receiving inebilizumab for ⩾4 years.
| Parameter | Participants (n = 75) |
|---|---|
| Age, mean (SD), years | 42.7 (11.1) |
| Female, n (%) | 70 (93.3) |
| Race, n (%) a | |
| American Indian/Alaskan Native | 5 (6.7) |
| Asian | 19 (25.3) |
| Black/African American | 7 (9.3) |
| White | 39 (52.0) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 10 (13.3) |
| Not Hispanic/Latino | 65 (86.7) |
| Weight, mean (SD), kg | 68.45 (17.91) |
| Body mass index, mean (SD), kg/m2 | 25.36 (5.30) |
| Height, mean (SD), cm | 163.62 (7.75) |
| Baseline EDSS | |
| Mean (SD) | 3.89 (1.64) |
| Median (range) | 3.50 (1.0–7.5) |
| Duration of inebilizumab, years | |
| Mean | 4.60 |
| Median (range) | 4.54 (4.01–5.53) |
| Assigned group in randomized controlled period, n (%) | |
| Inebilizumab | 65 (86.7) |
| Placebo | 10 (13.3) |
AQP4; aquaporin-4; Ig, immunoglobulin; SD: standard deviation; EDSS: Expanded Disability Status Scale.
a
Each category counts participants who selected only that demographic.